DexCom, Inc. (NASDAQ:DXCM) Stake Boosted by Intech Investment Management LLC

Intech Investment Management LLC increased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 60.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 622,788 shares of the medical device company's stock after purchasing an additional 235,458 shares during the quarter. DexCom accounts for 1.4% of Intech Investment Management LLC's investment portfolio, making the stock its 21st biggest holding. Intech Investment Management LLC owned approximately 0.16% of DexCom worth $48,434,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Versant Capital Management Inc purchased a new position in DexCom during the fourth quarter worth $25,000. Private Trust Co. NA increased its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after buying an additional 245 shares in the last quarter. Larson Financial Group LLC increased its position in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares in the last quarter. Heck Capital Advisors LLC purchased a new position in DexCom during the fourth quarter worth $38,000. Finally, SBI Securities Co. Ltd. purchased a new position in DexCom during the fourth quarter worth $49,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Down 1.7 %

Shares of DXCM traded down $1.31 during midday trading on Friday, reaching $73.80. 5,560,851 shares of the company were exchanged, compared to its average volume of 3,912,424. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The stock has a 50-day moving average price of $83.33 and a 200-day moving average price of $76.95. The company has a market cap of $28.84 billion, a price-to-earnings ratio of 51.61, a P/E/G ratio of 2.30 and a beta of 1.28.

Remove Ads

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on DXCM shares. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Canaccord Genuity Group raised their price target on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Citigroup lifted their price objective on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research report on Tuesday, March 4th. Finally, Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $99.82.

Insider Buying and Selling

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the business's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares of the company's stock, valued at $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Jacob Steven Leach sold 14,076 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the sale, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. This represents a 4.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is currently owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.